Understanding prostate cancer progression using patient-derived models
Patient-Derived Models of Prostate Cancer for Personalized Medicine
This study is looking at how metastatic prostate cancer changes when it stops responding to standard hormone therapy, using samples from patients to find out what makes their cancer unique, so we can create better, personalized treatment options just for them.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10683753 on NIH RePORTER |
What this research studies
This research focuses on metastatic prostate cancer that becomes resistant to standard hormone therapy. By using patient-derived models, such as xenografts and organoids, the study aims to analyze tumor specimens collected over time from the same patient. This approach will help identify the key molecular changes that drive cancer progression and resistance to treatment. Ultimately, the goal is to develop personalized treatment strategies based on the unique characteristics of each patient's cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with metastatic prostate cancer, particularly those whose cancer has progressed after hormone therapy.
Not a fit: Patients with early-stage prostate cancer or those who have not undergone hormone therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective, personalized treatment options for patients with advanced prostate cancer.
How similar studies have performed: Previous research using patient-derived models has shown promise in understanding cancer mechanisms and developing targeted therapies, indicating a strong potential for success in this approach.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Futreal, Phillip Andrew — University of Tx Md Anderson Can Ctr
- Study coordinator: Futreal, Phillip Andrew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.